These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35714110)

  • 1. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan.
    Yamamichi N; Shimamoto T; Takahashi Y; Takahashi M; Takeuchi C; Wada R; Fujishiro M
    PLoS One; 2022; 17(6):e0270252. PubMed ID: 35714110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores.
    Yamamichi N; Mochizuki S; Asada-Hirayama I; Mikami-Matsuda R; Shimamoto T; Konno-Shimizu M; Takahashi Y; Takeuchi C; Niimi K; Ono S; Kodashima S; Minatsuki C; Fujishiro M; Mitsushima T; Koike K
    BMC Med; 2012 May; 10():45. PubMed ID: 22554226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of the long-term outcome in reflux esophagitis in a low-prevalence gastroesophageal reflux disease region.
    Chang CS; Yang SS; Ko CW; Lien HC; Yeh HZ; Chen GH
    Scand J Gastroenterol; 2003 Nov; 38(11):1131-5. PubMed ID: 14686715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
    Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
    J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant, non-erosive esophagitis.
    Tokudome K; Funaki Y; Sasaki M; Izawa S; Tamura Y; Iida A; Ogasawara N; Konagaya T; Tokura Y; Kasugai K
    World J Gastroenterol; 2012 Nov; 18(41):5940-7. PubMed ID: 23139611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
    Takenaka R; Okada H; Kawano S; Komazawa Y; Yoshinaga F; Nagata S; Inoue M; Komatsu H; Onogawa S; Kushiyama Y; Mukai S; Todo H; Okanobu H; Manabe N; Tanaka S; Haruma K; Kinoshita Y
    World J Gastroenterol; 2016 Jun; 22(23):5430-5. PubMed ID: 27340360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Iwakiri K
    J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical treatments of reflux esophagitis - Proton pump inhibitors and histamine H2 receptor antagonists -].
    Kinoshita Y; Ishimura N
    Nihon Rinsho; 2016 Aug; 74(8):1304-1310. PubMed ID: 30562433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
    Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
    J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
    Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
    BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).
    Pohle T; Domschke W
    Langenbecks Arch Surg; 2000 Aug; 385(5):317-23. PubMed ID: 11026702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.